Premium
Does IL 28 B genotyping still have a role in the era of direct‐acting antiviral therapy for chronic hepatitis C infection?
Author(s) -
Holmes J. A.,
Desmond P. V.,
Thompson A. J.
Publication year - 2012
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12003
Subject(s) - telaprevir , boceprevir , ribavirin , genotype , pegylated interferon , medicine , interleukin 28b , genotyping , immunology , regimen , virology , sofosbuvir , viral load , hepatitis c virus , virus , biology , gene , genetics
Summary IL 28B genotype has been shown to be the strongest pretreatment predictor of sustained virological response ( SVR ) in patients with genotype 1 chronic hepatitis C infection ( CHC ) treated with pegylated interferon (peg‐ IFN ) and ribavirin ( RBV ). Patients carrying the good response genotype have a two‐ to threefold higher chance of SVR than those with a poor response genotype, manifest as dramatically improved early viral kinetics. However, the treatment paradigm for CHC is changing with the introduction of potent direct‐acting antivirals ( DAA s). IL 28B genotype remains relevant to both telaprevir and boceprevir treatment regimens, although the strength of association with virological response is attenuated. The association between IL 28B genotype and outcomes of treatment regimens that involve peg‐ IFN plus combination DAA therapy, or IFN ‐free regimens, is currently being evaluated. IL 28B genotype may remain relevant to individualizing the choice of treatment regimen in the future.